Clinical trial
A Two-stage Clinical Trial With Dose Escalation at the First Stage and a Single-blind, Placebo-controlled Clinical Trial for Evaluation of Efficacy, Safety, Reactogenicity and Immunogenicity of GNR-127 at the Second Stage in Patients With Allergic Rhinitis Sensitized to Birch Pollen.
NCT07155499 is registered in ClinicalTrials.gov with AO GENERIUM as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Two-stage Clinical Trial With Dose Escalation at the First Stage and a Single-blind, Placebo-controlled Clinical Trial for Evaluation of Efficacy, Safety, Reactogenicity and Immunogenicity of GNR-127 at the Second Stage in Patients With Allergic Rhinitis Sensitized to Birch Pollen.
- Lead sponsor
- AO GENERIUM
- Phase
- Phase 1/2
- Overall status
- Completed
- Start date
- October 7, 2024
- Completion date
- September 8, 2025
- Enrollment
- 150 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.